{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:02:29Z","timestamp":1791918149001,"version":"4.3.4"},"reference-count":65,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR136022"],"award-info":[{"award-number":["NIHR136022"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic tic disorders and Tourette syndrome typically present around age 5, with peak severity between ages 10 and 12. Treatment approaches vary by country and service availability and include psychoeducation, behavioural therapy, pharmacological therapies and deep brain stimulation. Digitally enabled interventions may improve outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluate the clinical and cost-effectiveness of two digital technologies, Online Remote Behavioural Treatment for Tics and Neupulse and identify evidence gaps for future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched major electronic databases (MEDLINE, EMBASE, Cochrane Library, Web of Science, and Cumulative Index to Nursing and Allied Health Literature) for published studies on clinical and cost-effectiveness. Data were extracted, assessed for bias using Cochrane risk-of-bias tool (version 2), and pooled using random-effects meta-analysis where appropriate. Cost-effectiveness was evaluated using a Markov cohort model with five tic severity states based on the Yale Global Tic Severity Scale \u2013 Total Tic Severity Score scale, from a United Kingdom National Health Service perspective. Model inputs were obtained from the Online Remote Behavioural Treatment for Tics study, company data, expert opinion and additional literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified three trials reported across 14 publications: 2 comparing Online Remote Behavioural Treatment for Tics with online psychoeducation, and 1 comparing Neupulse with sham stimulation and a waitlist control. All were assessed as low risk of bias. Meta-analysis of the 2 Online Remote Behavioural Treatment for Tics studies (445 participants) showed significantly lower Yale Global Tic Severity Scale \u2013 Total Tic Severity Score at 3 and 12 months compared to online psychoeducation. Results of secondary outcomes were mixed. Neupulse showed significantly lower Yale Global Tic Severity Scale \u2013 Total Tic Severity Score, and improvements in motor and phonic tic scores at 4 weeks compared to sham, but no differences in Yale Global Tic Severity Scale-Impairment or Premonitory Urge for Tics Scale \u2013 Revised scores.<\/jats:p>\n                    <jats:p>A definitive base-case incremental cost-effectiveness ratio could not be determined due to limited long-term data and uncertainty around long-term combinations of effectiveness and intervention costs in United Kingdom National Health Service practice. Probabilistic incremental cost-effectiveness ratios ranged from \u00a3642 per quality-adjusted life-year gained to Online Remote Behavioural Treatment for Tics being dominated. The probability of Online Remote Behavioural Treatment for Tics being cost-effective at a threshold value of \u00a320,000 per quality-adjusted life-year ranged from 52% to 89% across a range of scenarios. Cost-effectiveness results for Neupulse were even more uncertain due to a lack of published data, only a 4-week follow-up and uncertainty surrounding the intervention cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Evidence for Online Remote Behavioural Treatment for Tics and Neupulse was limited, with inconsistencies in the outcomes assessed. Comparators did not include face-to-face behavioural therapy and it was not possible to differentiate the effects of online delivery from those of exposure and response prevention. Cost-effectiveness results are uncertain due to a lack of long-term data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both Online Remote Behavioural Treatment for Tics and Neupulse appear to significantly reduce Yale Global Tic Severity Scale \u2013 Total Tic Severity Score, but there were no improvements in the Yale Global Tic Severity Scale-Impairment scores and mixed results across other secondary outcomes, meaning it is unclear to what extent improvements in tic severity scores can translate to improvements in quality of life. Cost-effectiveness estimates were highly uncertain due to a lack of long-term evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Future studies<\/jats:title>\n                    <jats:p>Replication studies are needed to confirm findings. Longer follow-up \u2013 particularly for Neupulse \u2013 is essential to understand sustained effects and long-term cost-effectiveness. More data on the natural course of tic severity and the sustainability of treatment effects would reduce uncertainty in economic modelling. Future research should also prioritise outcomes that reflect real-life impact on people\u2019s daily functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study is registered as PROSPERO CRD42024508045.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-9\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>\n                      This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136022) and is published in full in\n                      <jats:italic>Health Technology Assessment<\/jats:italic>\n                      ; Vol. 30, No. 8. See the NIHR Funding and Awards website for further award information.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/qlas8524","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T06:15:56Z","timestamp":1749708956000},"page":"1-67","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9786-8118","authenticated-orcid":true,"given":"Dwayne","family":"Boyers","sequence":"first","affiliation":[{"name":"Health Economics Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-884X","authenticated-orcid":true,"given":"Moira","family":"Cruickshank","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-3567","authenticated-orcid":true,"given":"Mohammad","family":"Azharuddin","sequence":"additional","affiliation":[{"name":"Health Economics Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-1795","authenticated-orcid":true,"given":"Paul","family":"Manson","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-3561","authenticated-orcid":true,"given":"Diane","family":"Swallow","sequence":"additional","affiliation":[{"name":"The Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6622-7839","authenticated-orcid":true,"given":"Carl","family":"Counsell","sequence":"additional","affiliation":[{"name":"The Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7576-6751","authenticated-orcid":true,"given":"Miriam","family":"Brazzelli","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"key2026020318093100_ref1-bib1","first-page":"581","article-title":"Prevalence of diagnosed Tourette syndrome in persons aged 6\u201317 years: United States, 2007","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR: Morb Mortal Wkly Rep"},{"key":"key2026020318093100_ref2-bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpsychores.2008.03.006","article-title":"The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies","volume":"65","author":"Robertson","year":"2008","journal-title":"J Psychosom Res"},{"key":"key2026020318093100_ref3-bib3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archpsyc.1993.01820210068008","article-title":"An epidemiologic study of Gilles de la Tourette\u2019s syndrome in Israel","volume":"50","author":"Apter","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"key2026020318093100_ref4-bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00787-021-01842-2","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment","volume":"31","author":"Szejko","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref6-bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamapsychiatry.2014.2650","article-title":"Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome","volume":"72","author":"Hirschtritt","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"key2026020318093100_ref7-bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpedi.160.1.65","article-title":"Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome","volume":"160","author":"Bloch","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key2026020318093100_ref8-bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaac.2017.01.010","article-title":"Course of Tourette syndrome and comorbidities in a large prospective clinical study","volume":"56","author":"Groth","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref9-bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpsychores.2009.09.002","article-title":"Clinical course of Tourette syndrome","volume":"67","author":"Bloch","year":"2009","journal-title":"J Psychosom Res"},{"key":"key2026020318093100_ref10-bib10","doi-asserted-by":"crossref","first-page":"112905","DOI":"10.1016\/j.psychres.2020.112905","article-title":"Interventions for tic disorders: an updated overview of systematic reviews and meta analyses","volume":"287","author":"Yang","year":"2020","journal-title":"Psychiatry Res"},{"key":"key2026020318093100_ref11-bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1212\/WNL.59.3.414","article-title":"The behavioral spectrum of tic disorders: a community-based study","volume":"59","author":"Kurlan","year":"2002","journal-title":"Neurology"},{"key":"key2026020318093100_ref12-bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"key":"key2026020318093100_ref13-bib13","volume-title":"Tic Disorders","author":"BMJ Best Practice","year":"2022"},{"key":"key2026020318093100_ref14-bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2012.05.002","article-title":"Prevalence of tic disorders: a systematic review and meta-analysis","volume":"47","author":"Knight","year":"2012","journal-title":"Pediatr Neurol"},{"key":"key2026020318093100_ref15-bib15","doi-asserted-by":"crossref","first-page":"109675","DOI":"10.1016\/j.pnpbp.2019.109675","article-title":"Meta-analysis: adulthood prevalence of Tourette syndrome","volume":"95","author":"Levine","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key2026020318093100_ref16-bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10597-011-9465-y","article-title":"The impact of Tourette syndrome in adults: results from the Tourette Syndrome Impact Survey","volume":"49","author":"Conelea","year":"2013","journal-title":"Community Ment Health J"},{"key":"key2026020318093100_ref17-bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12913-023-09753-5","article-title":"Patients\u2019 experience of accessing support for tics from primary care in the UK: an online mixed-methods survey","volume":"23","author":"Marino","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"key2026020318093100_ref18-bib18","volume-title":"Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87)","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2026020318093100_ref19-bib19","volume-title":"Autism Spectrum Disorder in under 19s: Recognition, Referral and Diagnosis (CG128)","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key2026020318093100_ref20-bib20","volume-title":"Autism Spectrum Disorder in under 19s: Support and Management (CG170)","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2026020318093100_ref21-bib21","volume-title":"Suspected Neurological Conditions: Recognition and Referral (NG127)","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2026020318093100_ref22-bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00787-021-01832-4","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders: summary statement","volume":"31","author":"M\u00fcller-Vahl","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref23-bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/070674371205700303","article-title":"Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation","volume":"57","author":"Steeves","year":"2012","journal-title":"Can J Psychiatry"},{"key":"key2026020318093100_ref24-bib24","volume-title":"Digitally Enabled Therapy for Chronic Tic Disorders and Tourette Syndrome in Children and Young People (GID-MT605): Final Protocol","author":"Aberdeen Health Technology Assessment Group","year":"2024"},{"key":"key2026020318093100_ref25-bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00787-021-01845-z","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part II: psychological interventions","volume":"31","author":"Andr\u00e9n","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref26-bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20040","article-title":"Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis","volume":"20","author":"Hollis","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2026020318093100_ref27-bib27","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/jcpp.12556","article-title":"Practitioner review: treatments for Tourette syndrome in children and young people \u2013 a systematic review","volume":"57","author":"Whittington","year":"2016","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026020318093100_ref28-bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment","volume":"20","author":"Roessner","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref29-bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(15)00008-3","article-title":"Bilateral globus pallidus stimulation for severe Tourette\u2019s syndrome: a double-blind, randomised crossover trial","volume":"14","author":"Kefalopoulou","year":"2015","journal-title":"Lancet Neurol"},{"key":"key2026020318093100_ref30-bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1474-4422(15)00043-5","article-title":"Design challenges for stimulation trials of Tourette\u2019s syndrome","volume":"14","author":"Jimenez-Shahed","year":"2015","journal-title":"Lancet Neurol"},{"key":"key2026020318093100_ref31-bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","article-title":"Efficacy and safety of deep brain stimulation in Tourette syndrome: the International Tourette Syndrome Deep Brain Stimulation Public Database and Registry","volume":"75","author":"Martinez-Ramirez","year":"2018","journal-title":"JAMA Neurol"},{"key":"key2026020318093100_ref32-bib32","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/jcm12072545","article-title":"Median nerve stimulation for treatment of tics: a 4-week open trial with ecological momentary assessment","volume":"12","author":"Iverson","year":"2023","journal-title":"J Clin Med"},{"key":"key2026020318093100_ref33-bib33","doi-asserted-by":"crossref","first-page":"e027583","DOI":"10.1136\/bmjopen-2018-027583","article-title":"Investigating a therapist-guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents \u2013 \u2018Online Remote Behavioural Intervention for Tics\u2019 (ORBIT) trial: protocol of an internal pilot study and single-blind randomised controlled trial","volume":"9","author":"Hall","year":"2019","journal-title":"BMJ Open"},{"key":"key2026020318093100_ref34-bib34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S2215-0366(21)00235-2","article-title":"Therapist-supported online remote behavioural intervention for tics in children and adolescents in England (ORBIT): a multicentre, parallel group, single-blind, randomised controlled trial","volume":"8","author":"Hollis","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"key2026020318093100_ref35-bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/CPMS3211","article-title":"Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation","volume":"27","author":"Hollis","year":"2023","journal-title":"Health Technol Assess"},{"key":"key2026020318093100_ref36-bib36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jnp.12313","article-title":"A double-blind, sham-controlled, trial of home-administered rhythmic 10-Hz median nerve stimulation for the reduction of tics, and suppression of the urge-to-tic, in individuals with Tourette syndrome and chronic tic disorder","volume":"17","author":"Maiquez","year":"2023","journal-title":"J Neuropsychol"},{"key":"key2026020318093100_ref37-bib37","volume-title":"Improving the Lives of People with Tourettes","author":"Neurotherapeutics Ltd"},{"key":"key2026020318093100_ref38-bib38","doi-asserted-by":"crossref","first-page":"e2225614","DOI":"10.1001\/jamanetworkopen.2022.25614","article-title":"Therapist-supported Internet-delivered exposure and response prevention for children and adolescents with Tourette Syndrome: a randomized clinical trial","volume":"5","author":"Andr\u00e9n","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key2026020318093100_ref39-bib39","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2026020318093100_ref40-bib40","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.cub.2020.04.044","article-title":"Entraining movement-related brain oscillations to suppress tics in Tourette syndrome","volume":"30","author":"Morera Maiquez","year":"2020","journal-title":"Curr Biol"},{"key":"key2026020318093100_ref41-bib41","doi-asserted-by":"crossref","first-page":"e248468","DOI":"10.1001\/jamanetworkopen.2024.8468","article-title":"Internet-delivered exposure and response prevention for pediatric Tourette Syndrome: 12-month follow-up of a randomized clinical trial","volume":"7","author":"Andr\u00e9n","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key2026020318093100_ref42-bib42","volume-title":"Telehealth Services for the Treatment of Psychiatric Issues: Clinical Effectiveness, Safety, and Guidelines (Rapid Review)","author":"Canadian Agency for Drugs and Technologies in Health","year":"2015"},{"key":"key2026020318093100_ref43-bib43","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key2026020318093100_ref44-bib44","volume-title":"Developing NICE Guidelines: The Manual (PMG20). Appendix H: Appraisal Checklists, Evidence Tables, GRADE and Economic Profiles","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key2026020318093100_ref45-bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3111\/13696998.2013.784591","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"16","author":"Husereau","year":"2013","journal-title":"J Med Econ"},{"key":"key2026020318093100_ref46-bib46","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-019-09521-8","article-title":"Economic evaluation of deep-brain stimulation for Tourette\u2019s syndrome: an initial exploration","volume":"266","author":"Dang","year":"2019","journal-title":"J Neurol"},{"key":"key2026020318093100_ref47-bib47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/jcpp.13756","article-title":"Long\u2010term clinical and cost\u2010effectiveness of a therapist\u2010supported online remote behavioural intervention for tics in children and adolescents: extended 12\u2010 and 18\u2010month follow\u2010up of a single\u2010blind randomised controlled trial","volume":"64","author":"Hollis","year":"2023","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026020318093100_ref48-bib48","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2026020318093100_ref49-bib49","volume-title":"NICE Health Technology Evaluations: The Manual (PMG36)","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2026020318093100_ref50-bib50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","article-title":"The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity","volume":"28","author":"Leckman","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key2026020318093100_ref51-bib51","volume-title":"National Life Tables: UK","author":"Office for National Statistics","year":"2024"},{"key":"key2026020318093100_ref52-bib52","volume-title":"GID-MT605 Digitally Enabled Therapy for Chronic Tic Disorders and Tourette Syndrome Final Scope \u2013 Updated","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"key2026020318093100_ref53-bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12955-015-0218-4","article-title":"The validity of the Child Health Utility instrument (CHU9D) as a routine outcome measure for use in child and adolescent mental health services","volume":"13","author":"Furber","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"key2026020318093100_ref54-bib54","first-page":"11","article-title":"The Child Health Utility 9D (CHU9D) A new paediatric preference based measure of health related quality of life","volume":"43","author":"Stevens","year":"2010","journal-title":"PRO Newsletter"},{"key":"key2026020318093100_ref55-bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11587350-000000000-00000","article-title":"Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation","volume":"9","author":"Stevens","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"key2026020318093100_ref56-bib56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2026020318093100_ref57-bib57","volume-title":"The Guidelines Manual: Process and Methods (PMG6)","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key2026020318093100_ref58-bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X03255922","article-title":"Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework","volume":"23","author":"Briggs","year":"2003","journal-title":"Med Decis Making"},{"key":"key2026020318093100_ref59-bib59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40273-014-0186-2","article-title":"Avoiding and identifying errors and other threats to the credibility of health economic models","volume":"32","author":"Tappenden","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key2026020318093100_ref60-bib60","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1186\/s13063-020-04902-1","article-title":"Opportunities and challenges of delivering digital clinical trials: lessons learned from a randomised controlled trial of an online behavioural intervention for children and young people","volume":"21","author":"Hall","year":"2020","journal-title":"Trials"},{"key":"key2026020318093100_ref61-bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/jcpp.13756","article-title":"Long\u2010term clinical and cost\u2010effectiveness of a therapist\u2010supported online remote behavioural intervention for tics in children and adolescents: extended 12\u2010 and 18\u2010month follow\u2010up of a single\u2010blind randomised controlled trial","volume":"64","author":"Hollis","year":"2023","journal-title":"J Child Psychol Psychiatry"},{"key":"key2026020318093100_ref62-bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13063-019-3974-3","article-title":"Protocol for the process evaluation of the Online Remote Behavioural Intervention for Tics (ORBIT) randomized controlled trial for children and young people","volume":"21","author":"Khan","year":"2020","journal-title":"Trials"},{"key":"key2026020318093100_ref63-bib63","doi-asserted-by":"crossref","first-page":"e25470","DOI":"10.2196\/25470","article-title":"Fidelity of delivery and contextual factors influencing children's level of engagement: process evaluation of the Online Remote Behavioral Intervention for Tics Trial","volume":"23","author":"Khan","year":"2021","journal-title":"J Med Internet Res"},{"key":"key2026020318093100_ref64-bib64","first-page":"197","article-title":"Factors influencing the efficacy of an online behavioural intervention for children and young people with tics: Process evaluation of a randomised controlled trial J Behav Cogn Ther","volume":"32","author":"Khan","year":"2022"},{"key":"key2026020318093100_ref65-bib65","doi-asserted-by":"crossref","first-page":"e024685","DOI":"10.1136\/bmjopen-2018-024685","article-title":"Therapist-guided and parent-guided internet-delivered behaviour therapy for paediatric Tourette\u2019s disorder: a pilot randomised controlled trial with long-term follow-up","volume":"9","author":"Andr\u00e9n","year":"2019","journal-title":"BMJ open"},{"key":"key2026020318093100_ref66-bib66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s13063-021-05592-z","article-title":"Efficacy and cost-effectiveness of therapist-guided internet-delivered behaviour therapy for children and adolescents with Tourette syndrome: study protocol for a single-blind randomised controlled trial","volume":"22","author":"Andr\u00e9n","year":"2021","journal-title":"Trials"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/QLAS8524\/QLAS8524.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2049891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:44:05Z","timestamp":1770122645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/QLAS8524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":65,"alternative-id":["10.3310\/QLAS8524"],"URL":"https:\/\/doi.org\/10.3310\/qlas8524","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"01-2024","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"08-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"07-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}